Table Of Contents

1. Introduction

 1.1 Market Definition & Scope

 1.2 Research Assumptions & Abbreviations

 1.3 Research Methodology

2. Executive Summary

 2.1 Market Snapshot

 2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2035

 2.3 Market Size & Forecast, By Segmentation, 2022–2035

  2.3.1 Market Size By Product

  2.3.2 Market Size By Source

  2.3.3 Market Size By Disease Category

  2.3.4 Market Size By Manufacturing

 2.4 Market Share & Bps Analysis By Region, 2025

 2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic

 2.6 Industry CxO’s Perspective

3. Market Overview

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Key Market Trends

 3.2 Industry PESTLE Analysis

 3.3 Key Industry Forces (Porter’s) Impacting Market Growth

 3.4 Industry Supply Chain Analysis

  3.4.1 Raw Material Suppliers

  3.4.2 Manufacturers

  3.4.3 Distributors/Suppliers

  3.4.4 Customers/End-Users

 3.5 Industry Life Cycle Assessment

 3.6 Parent Market Overview

 3.7 Market Risk Assessment

4. Statistical Insights & Trends Reporting

4.1 Pricing Analysis & Cost Structure

  4.1.1 Pricing Models: Per-dose pricing, hospital procurement contracts, value-based reimbursement models

  4.1.2 Average Cost Metrics: Cost variation across monoclonal antibodies, vaccines, recombinant proteins, gene therapies

  4.1.3 Cost Structure Breakdown: R&D, clinical trials, bioprocessing, cell culture, purification, regulatory compliance

  4.1.4 Price Benchmarking by Therapy Type: Oncology biologics, autoimmune biologics, rare disease biologics

  4.1.5 Forecasted Pricing Trends: Biosimilar-driven price erosion, personalized biologics premium pricing

4.2 Production & Manufacturing Metrics

  4.2.1 Bioproduction Capacity Metrics: Total global bioreactor capacity utilization

  4.2.2 Manufacturing Mode Metrics: In-house vs contract manufacturing share

  4.2.3 Cell Line Productivity Metrics: Output per cell culture batch

  4.2.4 Bioprocess Efficiency Metrics: Yield per liter of bioreactor volume

  4.2.5 Scale-Up Metrics: Time and success rate from lab to commercial production

4.3 Product & Therapy Distribution Metrics

  4.3.1 Product Mix Metrics: Monoclonal antibodies, vaccines, recombinant proteins, cell & gene therapies

  4.3.2 Therapeutic Area Share Metrics: Oncology, autoimmune diseases, infectious diseases, rare diseases

  4.3.3 Biosimilar Penetration Metrics: Share of biosimilars vs originator biologics

  4.3.4 Pipeline Conversion Metrics: Clinical trial success to commercial approval rate

  4.3.5 Novel Therapy Adoption Metrics: Uptake of gene and cell therapies

4.4 Clinical & Development Metrics

  4.4.1 Clinical Trial Success Rates: Phase I–III progression efficiency

  4.4.2 Development Cycle Time Metrics: Average biologic development duration

  4.4.3 R&D Intensity Metrics: Clinical trial count per therapeutic area

  4.4.4 Regulatory Approval Metrics: Approval rate of biologic drug applications

  4.4.5 Innovation Pipeline Metrics: Number of biologics in late-stage development

4.5 Patient & Treatment Utilization Metrics

  4.5.1 Patient Adoption Metrics: Number of patients treated with biologics annually

  4.5.2 Treatment Frequency Metrics: Dose frequency per therapy type

  4.5.3 Prescription Share Metrics: Biologics vs small molecule drug usage

  4.5.4 Therapy Persistence Metrics: Treatment continuation rates

  4.5.5 Outcome Improvement Metrics: Clinical effectiveness across disease categories

5. Biologics Market Segmental Analysis & Forecast, By Product, 2022–2035, Value (USD Billion)

5.1 Introduction

 5.2 Monoclonal Antibodies

  5.2.1 Key Trends

  5.2.2 Market Size & Forecast, 2022–2035

 5.2.3 MABs By Source

 5.2.4 MABs By Disease Category

 5.3 Vaccines

 5.4 Recombinant Proteins

 5.5 Antisense & RNAi Therapeutics

 5.6 Others

6. Biologics Market Segmental Analysis & Forecast, By Source, 2022–2035, Value (USD Billion)

    6.1 Introduction

 6.2 Microbial

  6.2.1 Key Trends

  6.2.2 Market Size & Forecast, 2022–2035

 6.3 Mammalian

 6.4 Others

7. Biologics Market Segmental Analysis & Forecast, By Disease Category, 2022–2035, Value (USD Billion)

    7.1 Introduction

 7.2 Oncology

  7.2.1 Key Trends

  7.2.2 Market Size & Forecast, 2022–2035

 7.3 Infectious Diseases

 7.4 Immunological Disorders

 7.5 Cardiovascular Disorders

 7.6 Hematological Disorders

 7.7 Others

8. Biologics Market Segmental Analysis & Forecast, By Manufacturing, 2022–2035, Value (USD Billion)

    8.1 Introduction

 8.2 Outsourced

  8.2.1 Key Trends

  8.2.2 Market Size & Forecast, 2022–2035

 8.3 In-house

9. Biologics Market Segmental Analysis & Forecast By Region, 2022–2035, Value (USD Billion)

9.1 Introduction

9.2 North America

 9.2.1 Key Trends

 9.2.2 Biologics Market Size & Forecast, By Product, 2022–2035

 9.2.3 Biologics Market Size & Forecast, By Source, 2022–2035

 9.2.4 Biologics Market Size & Forecast, By Disease Category, 2022–2035

 9.2.5 Biologics Market Size & Forecast, By Manufacturing, 2022–2035

 9.2.6 Biologics Market Size & Forecast, By Country, 2022–2035

  9.2.6.1 USA

  9.2.6.2 Canada

9.3 Europe

 9.3.1 Key Trends

 9.3.2 Biologics Market Size & Forecast, By Product, 2022–2035

 9.3.3 Biologics Market Size & Forecast, By Source, 2022–2035

 9.3.4 Biologics Market Size & Forecast, By Disease Category, 2022–2035

 9.3.5 Biologics Market Size & Forecast, By Manufacturing, 2022–2035

 9.3.6 Biologics Market Size & Forecast, By Country, 2022–2035

  9.3.6.1 Germany

  9.3.6.2 UK

  9.3.6.3 France

  9.3.6.4 Italy

  9.3.6.5 Spain

  9.3.6.6 Russia

  9.3.6.7 Poland

  9.3.6.8 Rest of Europe

9.4 Asia-Pacific

 9.4.1 Key Trends

 9.4.2 Biologics Market Size & Forecast, By Product, 2022–2035

 9.4.3 Biologics Market Size & Forecast, By Source, 2022–2035

 9.4.4 Biologics Market Size & Forecast, By Disease Category, 2022–2035

 9.4.5 Biologics Market Size & Forecast, By Manufacturing, 2022–2035

 9.4.6 Biologics Market Size & Forecast, By Country, 2022–2035

  9.4.6.1 China

  9.4.6.2 India

  9.4.6.3 Japan

  9.4.6.4 South Korea

  9.4.6.5 Australia

  9.4.6.6 ASEAN Countries

  9.4.6.7 Rest of Asia-Pacific

9.5 Latin America

 9.5.1 Key Trends

 9.5.2 Biologics Market Size & Forecast, By Product, 2022–2035

 9.5.3 Biologics Market Size & Forecast, By Source, 2022–2035

 9.5.4 Biologics Market Size & Forecast, By Disease Category, 2022–2035

 9.5.5 Biologics Market Size & Forecast, By Manufacturing, 2022–2035

 9.5.6 Biologics Market Size & Forecast, By Country, 2022–2035

  9.5.6.1 Brazil

  9.5.6.2 Argentina

  9.5.6.3 Mexico

  9.5.6.4 Colombia

  9.5.6.5 Rest of Latin America

9.6 Middle East & Africa

 9.6.1 Key Trends

 9.6.2 Biologics Market Size & Forecast, By Product, 2022–2035

 9.6.3 Biologics Market Size & Forecast, By Source, 2022–2035

 9.6.4 Biologics Market Size & Forecast, By Disease Category, 2022–2035

 9.6.5 Biologics Market Size & Forecast, By Manufacturing, 2022–2035

 9.6.6 Biologics Market Size & Forecast, By Country, 2022–2035

  9.6.6.1 UAE

  9.6.6.2 Saudi Arabia

  9.6.6.3 Qatar

  9.6.6.4 Egypt

  9.6.6.5 South Africa

  9.6.6.6 Rest of Middle East & Africa

10. Competitive Landscape

 10.1 Key Players' Positioning

 10.2 Competitive Developments

  10.2.1 Key Strategies Adopted (%), By Key Players, 2025

  10.2.2 Year-Wise Strategies & Development, 2022–2025

  10.2.3 Number Of Strategies Adopted By Key Players, 2025

 10.3 Market Share Analysis, 2025

 10.4 Product/Service & Application Benchmarking

  10.4.1 Product/Service Specifications & Features By Key Players

  10.4.2 Product/Service Heatmap By Key Players

  10.4.3 Application Heatmap By Key Players

 10.5 Industry Start-Up & Innovation Landscape

10.6 Key Company Profiles

10.6.1 Samsung Biologics

 10.6.1.1 Company Overview & Snapshot

 10.6.1.2 Product/Service Portfolio

 10.6.1.3 Key Company Financials

 10.6.1.4 SWOT Analysis

10.6.2 Amgen Inc.

10.6.3 AbbVie Inc.

10.6.4 Novo Nordisk A/S

10.6.5 F. Hoffmann-La Roche Ltd.

10.6.6 Pfizer Inc.

10.6.7 Sanofi S.A.

10.6.8 Johnson & Johnson Services, Inc.

10.6.9 Celltrion Healthcare Co., Ltd.

10.6.10 Bristol-Myers Squibb Company

10.6.11 Eli Lilly and Company

10.6.12 Merck & Co., Inc.

10.6.13 AstraZeneca plc

10.6.14 Gilead Sciences, Inc.

10.6.15 Novartis AG

10.6.16 Regeneron Pharmaceuticals, Inc.

10.6.17 Takeda Pharmaceutical Company

10.6.18 Biogen Inc.

10.6.19 Genentech (Roche)

10.6.20 CSL Behring

11. Analyst Recommendations

 11.1 SNS Insider Opportunity Map

 11.2 Industry Low-Hanging Fruit Assessment

 11.3 Market Entry & Growth Strategy

 11.4 Analyst Viewpoint & Suggestions on Market Growth

12. Assumptions

13. Disclaimer

14. Appendix

 14.1 List Of Tables

 14.2 List Of Figures